Laurus Labs Limited

BSE:540222 Stock Report

Market Cap: ₹314.7b

Laurus Labs Past Earnings Performance

Past criteria checks 1/6

Laurus Labs's earnings have been declining at an average annual rate of -6.1%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 11.5% per year. Laurus Labs's return on equity is 3.2%, and it has net margins of 2.6%.

Key information

-6.1%

Earnings growth rate

-6.2%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate11.5%
Return on equity3.2%
Net Margin2.6%
Next Earnings Update24 Jan 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Laurus Labs makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:540222 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2450,5321,3116,8170
30 Jun 2450,5401,4826,6690
31 Mar 2450,4081,6066,5290
31 Dec 2349,8211,8796,3200
30 Sep 2353,3203,6786,2440
30 Jun 2356,8345,6376,0740
31 Mar 2360,4067,9015,9950
31 Dec 2260,8459,1765,7860
30 Sep 2255,6848,6835,5320
30 Jun 2251,9608,3745,2910
31 Mar 2249,3568,2755,0430
31 Dec 2149,2278,9374,8990
30 Sep 2151,82310,1284,6850
30 Jun 2151,17710,5324,5370
31 Mar 2148,1359,8364,3800
31 Dec 2042,4077,9714,1900
30 Sep 2036,8195,9774,0680
30 Jun 2032,5554,1203,8660
31 Mar 2028,3172,5533,5540
31 Dec 1926,2771,8833,4520
30 Sep 1924,2761,3263,2570
30 Jun 1923,0359233,1120
31 Mar 1922,9199383,0370
31 Dec 1822,1709572,9420
30 Sep 1821,6651,1272,9010
30 Jun 1821,1681,4532,8000
31 Mar 1820,5621,6762,6990
31 Dec 1719,6871,9172,8700
30 Sep 1719,9542,0192,7720
30 Jun 1719,7332,0142,6730
31 Mar 1719,0461,8812,3490
31 Mar 1617,7761,3371,9830
31 Mar 1513,2666841,7480
31 Mar 1411,5979721,4730

Quality Earnings: 540222 has high quality earnings.

Growing Profit Margin: 540222's current net profit margins (2.6%) are lower than last year (6.9%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 540222's earnings have declined by 6.1% per year over the past 5 years.

Accelerating Growth: 540222's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 540222 had negative earnings growth (-64.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20.5%).

Return on Equity

High ROE: 540222's Return on Equity (3.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 02:04
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Laurus Labs Limited is covered by 23 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prashant NairAmbit Capital
Nitin BhasinAmbit Capital
null nullAntique Stockbroking Ltd.